Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
Go back to Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM| (NASDAQ: BBIO) | Delayed: 76.08 +1.32 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.76 | 52 Week High | $ | |||
| Open | $73.63 | 52 Week Low | $ | |||
| Day High | $76.81 | P/E | N/A | |||
| Day Low | $73.47 | EPS | $ | |||
| Volume | 2,286,014 | |||||
